Search Results
Mar 05, 2026, 17:31 ET Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
top-line results from the Phase II VIBRANT trial evaluating verekitug for the treatment of CRSwNP. In the 24-week study, verekitug administered at 100 mg every 12 weeks met its primary endpoint, demonstrating a statistically significant and clinically meaningful placebo-adjusted reduction in endoscopic
More news about: DelveInsight Business Research, LLP
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing
More news about: Johnson & Johnson
Mar 05, 2026, 09:30 ET Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
remittersParticipants randomized to both 20 mg and 2mg dosing arms experienced meaningful subjective effects and showed clinically significant responses over SoC, with 59% meeting the criteria for response and 32% for remission in the 20mg arm and a 30% responder and remitter rate in the 2mg arm at week 6.Commercially
More news about: Market News Updates
Mar 05, 2026, 09:00 ET Tanabe Pharma America to Highlight Research in ALS at 2026 MDA Clinical and Scientific Conference
treatment cycle. For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. Each 105 mg (5mL) dose of RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after
More news about: Tanabe Pharma America
Mar 05, 2026, 06:00 ET Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
effective for use in children.Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and
More news about: Eli Lilly and Company
Mar 04, 2026, 09:02 ET The Coffee Bean & Tea Leaf® Springs Into The Season With New Energy-Forward Beverages
Brew Tea, lightly sweetened and infused with real fruit pieces for an uplifting taste and texture. The natural energy boost, an additional 80mg / regular and 120mg / large, comes from green coffee and tea extract, infused with Vitamin B12 and no added sugars, delivering a balanced lift that keeps pace
More news about: The Coffee Bean & Tea Leaf
Mar 04, 2026, 09:00 ET Altruist Biologics Launches Altru-CON™ High-Concentration Formulation Platform to Accelerate Biologics Development
through high-concentration formulation.The platform can reduce IND timelines to under nine months and achieve stable formulation for up to 200 mg/mL subcutaneous administration.HANGZHOU, China, March 4, 2026
More news about: Altruist Biologics
Mar 04, 2026, 09:00 ET Altruist Biologics Launches Altru-CON™ High-Concentration Formulation Platform to Accelerate Biologics Development
through high-concentration formulation.The platform can reduce IND timelines to under nine months and achieve stable formulation for up to 200 mg/mL subcutaneous administration.HANGZHOU, China, March 4, 2026
More news about: Altruist Biologics
Mar 04, 2026, 02:30 ET ANANDA PHARMA LTD ("Ananda" or the "Company") : MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis
Women's Health Plan.The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment
More news about: Ananda Pharma Limited
Mar 03, 2026, 17:12 ET Micross Introduces H+ Screened DC-DC Converters for LEO Constellations and New Space Missions
radiography to support reliability in LEO and new space environments. The AFLS series offers radiation specifications of 50kRad (Si) TID and 60MeV•cm²/mg SEE.Derived from the AFL series, which has a proven track record in defense applications such as PAC-3 and Patriot Missile systems, the AFLS
More news about: Micross Components
Mar 03, 2026, 17:00 ET CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
trials, demonstrating a well-established safety profile. The trial enrolled 41 DMD patients who received either low dose ifetroban (150 mg per day), high dose ifetroban (300 mg per day) or placebo. The study's primary endpoint was an improvement in the heart's left ventricular ejection fractions (LVEF). Key
More news about: Cumberland Pharmaceuticals Inc.
Mar 03, 2026, 16:05 ET Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
patients were enrolled in the initial cohorts of the Phase 1b trial. Patients were first enrolled in the 80 mg once daily (QD) cohort. Subsequent patients were randomized to either 60 mg QD or 120 mg QD.Patients enrolled were heavily pretreated, consistent with patients from previously reported datasets.
More news about: Enliven Therapeutics, Inc.
Mar 03, 2026, 16:01 ET Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
announced enrollment of the first patient in the dose expansion phase of the study, where up to 40 patients will be randomized to receive either 500 mg once daily (QD) or twice daily (BID) to determine the recommended Phase 2 dose for future clinical trials.Rigel is on track to complete enrollment
More news about: Rigel Pharmaceuticals, Inc.
Mar 03, 2026, 11:03 ET JungKwanJang Showcases 127 Years of Korean Red Ginseng Heritage at Natural Products Expo West 2026
containing product samplesVisitors can also explore JungKwanJang's diverse product offerings, including liquid extract sticks like Everytime 2,000mg, concentrated extracts, tea, capsules, and root powders, providing multiple ways to enjoy ginseng daily. The booth will feature Korean-style bojagi
More news about: Jung Kwan Jang
Mar 03, 2026, 10:05 ET Creatv Bio's LifeTracDx® Blood Test Utilized as Exploratory Biomarker in CytoDyn's Phase 2 Study in Patients with Relapsed/Refractory Metastatic Colorectal Cancer
microenvironment.In prior studies, leronlimab induced PD-L1 expression on CTCs and CAMLS in 88% of metastatic breast cancer patients treated at doses above 525 mg/week, reinforcing the proposed ability of CCR5 blockade to convert "cold" tumors into "hot," PD-L1–positive tumors. In addition, changes observed in circulating
More news about: Creatv MicroTech, Inc.
Mar 03, 2026, 09:45 ET Electrolit Turns Up the Chill with Launch of New Cherry Ice Flavor, Now Nationwide
nationwide launch of a new 21-oz ready-to-drink Cherry Ice. Cherry Ice delivers a crisp cherry taste with a refreshing, icy finish and is balanced with 1,670 mg of electrolytes to support instant rehydration and recovery after workouts, travel, or busy days on the go.
More news about: Electrolit
Mar 03, 2026, 09:00 ET Power Metallic Intercepts Lion Style Sulphides (Lion East and Lion West) Following Recently Recognized High Grade Structural Trends
indications of polymetallic mineralization include Pd (up to 0.10 g/t), Pt (0.11 g/t) in hole PMX-25-015, and Au (0.36 g/t) in hole PMX-25-001 in the high Mg rocks.The four holes test an area of more than 2 km of strike along the prospective EM targets, and drill holes are hundreds of meters apart.
More news about: Power Metallic Mines Inc.
Mar 03, 2026, 07:30 ET Keenova Publishes XIAFLEX® (collagenase clostridium histolyticum) Analysis in Journal of Hand Surgery Global Online
patients taking low-dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration
More news about: Keenova Therapeutics
Mar 03, 2026, 07:19 ET Natural Grocers® Softens the Spring Forward with Savings and Sleep-Smart Support
PricesSM March 7–10.[iv]Yachak Organic, Organic Yerba Mate Energy Drinks ($1.69/each)Natrol® Melatonin 3 mg Time Release ($8.99/100 tab)Perfect Food Bars®, Protein Bars ($13.19/8 ct)Nixie® Organic Sparkling Waters ($4.79/8 pk)Boiron®
More news about: Natural Grocers by Vitamin Cottage, Inc.
Mar 03, 2026, 06:00 ET GOED Celebrates 20 Years of Worldwide Leadership on Global Omega-3 Day
salmon, sardines or mackerel) at least twice a week.Take an omega-3 supplement made from fish, krill or algal oils to reach the recommended 500mg daily intake.Choose EPA/DHA fortified foods and beverages like milk and yogurt when available as options.Looking Ahead: The
More news about: GOED Omega-3
Mar 02, 2026, 16:05 ET Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
selective Kv7 channel activator, the majority of participants who completed at least 6 months of open-label extension (OLE) treatment with opakalim 75 mg once daily showed ≥50% reductions in seizure frequency compared to pretreatment baseline. Opakalim was well-tolerated in the OLE with a low incidence
More news about: Biohaven Ltd.
Mar 02, 2026, 16:05 ET Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.
Mar 02, 2026, 14:32 ET Cognizin® Citicoline Powers Happy Panda™'s New Functional Energy Drink Launch
formulation combines Cognizin® Citicoline, supported by more than a decade of clinical research for cognitive performance and mental clarity, with 150 mg of natural caffeine and L-theanine for balanced energy without jitters. The beverage also includes B vitamins and electrolytes, with under 5 calories
More news about: Kyowa Hakko U.S.A
Mar 02, 2026, 10:32 ET Breckenridge launches Pomalidomide Capsules, strengthening its oncology portfolio
failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1 mg, 2 mg, 3 mg, and 4 mg strengths and is distributed primarily through specialty pharmacies and clinics. Full prescribing information, including boxed warnings for Breckenridge's Pomalidomide
More news about: Breckenridge Pharmaceutical, Inc.
Mar 02, 2026, 09:00 ET Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®
(H1) treatment. A total of 202 patients were enrolled and randomly assigned to one of three LP-003 treatment groups (100 mg Q4W, 200 mg Q4W, 200 mg Q8W), the Omalizumab group (300 mg Q4W), or the placebo group, with a total treatment duration of 24 weeks. In this head-to-head trial against
More news about: LongBio